Clatterbridge Cancer Centre Biobank
The Clatterbridge Cancer Centre (CCC) has a well-defined mission to ‘improve health and wellbeing through compassionate, safe and effective cancer care’. Research for patient benefit is a fundamental part of CCC to conduct high quality research which translates into improved treatment and better prognosis for our patients. We established the CCC Biobank aims to provide high quality biological samples linked to patient outcome data to facilitate good quality research into the molecular mechanisms of cancer, biomarker discovery for early detection of cancer, patient stratification and into the reasons why some cohorts of patients fail to respond to therapeutic agents; all of which it is hoped will result in tangible patient benefit. The sample collection is entirely prospective following full informed consent from CCC patients diagnosed with cancer. The Biobank will also store samples donated from ‘healthy volunteers’ who have not been diagnosed with cancer in order to provide age matched controls. The samples will be used for the following cancer research procedures including, discovery and validation of: • Diagnostic biomarkers • Prognostic biomarkers • Predictive biomarkers • Biomarkers for emerging drug resistance • Biomarkers of toxicity • Molecular mechanisms of cancer The samples range across all cancer types and stage.
- Access to the full pathology archive
The Clatterbridge Cancer Centre NHS Foundation Trust
Last Updated: 26/08/2021
|Year||Access Requests Received||Access Requests Approved|